血红蛋白α珠蛋白链在体外增强组织型纤溶酶原激活剂诱导的高纤溶状态
该研究对30例严重创伤患者(输血前,按纤溶状态分层)及10例健康对照进行蛋白质组学分析,并将完整血红蛋白A、α/β珠蛋白链或生理盐水加入全血,用tPA激发的血栓弹力图评估纤溶程度。结果仅α和β珠蛋白链在高纤溶患者中升高(p<0.01);α珠蛋白链(而非血红蛋白A或β链)缩短反应时间并显著增加溶解时间30(p<0.05);表面等离子共振显示α珠蛋白链与纤溶酶原的结合动力学类似tPA:纤溶酶原,并增强tPA诱导的纤溶酶活性。结论提示α珠蛋白链可能作为严重创伤时组织损伤和失血性休克释放的循环「兼职」介质促进高纤溶。
要点
- 严重创伤患者中约25%发生系统性高纤溶,死亡率高达70%,高纤溶状态与α和β珠蛋白链升高相关(p<0.01)。
- α珠蛋白链在体外缩短tPA激发血栓弹力图的反应时间并显著增加溶解时间30(p<0.05),而完整血红蛋白A和β链无此作用。
- α珠蛋白链与纤溶酶原的结合动力学类似tPA与纤溶酶原,并增强tPA诱导的纤溶酶活性。
- 该研究为体外实验,α珠蛋白链促成高纤溶的机制可能为结合纤溶酶原并增强纤溶酶活性。
- 证据等级为预后性III级,尚不能据此改变床旁抗纤溶治疗决策。
适用人群与场景
- 30例严重创伤患者(血液成分复苏前,按纤溶状态分层)及10例健康对照,均为体外实验样本。
- 原文未提及急诊、ICU或院前场景及病情阶段的具体限定。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型为体外实验结合30例严重创伤患者(输血前,按纤溶状态分层)及10例健康对照的蛋白质组学分析,单中心试点研究。
- 仅α和β珠蛋白链在高纤溶患者中升高(p<0.01)。
- α珠蛋白链(而非血红蛋白A或β珠蛋白链)在枸橼酸化原生血栓弹力图上缩短反应时间并显著增加溶解时间30(p<0.05)。
- α珠蛋白链与纤溶酶原的结合动力学类似tPA:纤溶酶原,并增强tPA诱导的纤溶酶活性。
证据类型、等级与局限
- 证据类型为体外实验结合小样本蛋白质组学分析,证据等级为预后性III级。
- 局限:原文未明确列出局限;设计本身为体外实验、样本量小(30例患者+10例对照)、单中心试点研究。
对床旁实践的改变
- 该体外研究提示α珠蛋白链可能作为严重创伤后高纤溶的循环介质,但尚不能据此改变急诊/ICU床旁抗纤溶治疗或输血决策。
- 适用人群为严重创伤患者(血液成分复苏前),不适用于非创伤患者;原文未提及排除人群。
- 常见陷阱:将体外实验结果直接外推为临床治疗靶点或决策阈值。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Severe injury predisposes patients to trauma-induced coagulopathy, which may be subdivided by the state of fibrinolysis. Systemic hyperfibrinolysis (HF) occurs in approximately 25% of these patients with mortality as high as 70%. Severe injury also causes the release of numerous intracellular proteins, which may affect coagulation, one of which is hemoglobin, and hemoglobin substitutes induce HF in vitro. We hypothesize that the α-globin chain of hemoglobin potentiates HF in vitro by augmenting plasmin activity.
METHODS: Proteomic analysis was completed on a pilot study of 30 injured patients before blood component resuscitation, stratified by their state of fibrinolysis, plus 10 healthy controls. Different concentrations of intact hemoglobin A, the α- and β-globin chains, or normal saline (controls) were added to whole blood, and tissue plasminogen activator (tPA)-challenged thrombelastography was used to assess the degree of fibrinolysis. Interactions with plasminogen (PLG) were evaluated using surface plasmon resonance. Tissue plasminogen activator-induced plasmin activity was evaluated in the presence of the α-globin chain.
RESULTS: Only the α- and β-globin chains increased in HF patients (p < 0.01). The α-globin chain but not hemoglobin A or the β-globin chain decreased the reaction time and significantly increased lysis time 30 on citrated native thrombelastographies (p < 0.05). The PLG and α-globin chain had interaction kinetics similar to tPA:PLG, and the α-globin chain increased tPA-induced plasmin activity.
CONCLUSIONS: The α-globin chain caused HF in vitro by binding to PLG and augmenting plasmin activity and may represent a circulating "moonlighting" mediator released by the tissue damage and hemorrhagic shock inherent to severe injury.
LEVEL OF EVIDENCE: Prognostic, level III.
参考来源
- Morton AP, Hadley JB, Ghasabyan A, et al. The α-globin chain of hemoglobin potentiates tissue plasminogen activator induced hyperfibrinolysis in vitro. J Trauma Acute Care Surg. 2022. PMID: 34538821. doi:10.1097/TA.0000000000003410
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。